Glucose Supplement Recalled; ADA Sued by Former Employee; Forteo Generic OK’d

The FDA announced a voluntary recall of an over-the-counter glucose support supplement for the presence of metformin and glyburide.

Over the past two decades, the prevalence of diabetes and obesity, respectively, increased from 7.8% to 14.9% and from 33% to 44% among higher-income, middle-age Americans. (Annals of Internal Medicine)

Former director of nutrition for the American Diabetes Association sued the organization after she was allegedly fired for objecting to the promotion of sugar substitute Splenda. (Reuters)

Two metabolites may help predict which Hispanic youth are more likely to develop prediabetes. (Diabetes Care)

The FDA approved a generic version of teriparatide injection (Forteo) for certain adults with osteoporosis, said Teva Pharmaceuticals.

Referral to a large-scale, established behavior change program for prediabetes improved HbA1c, researchers found. (Nature)

Following a meeting with the FDA in August, Ascendis Pharma resubmitted its hypoparathyroidism treatment palopegteriparatide (TransCon PTH) for approval.

After surveying 31 perimenopausal women about their periods, researchers suggested comprehensive menstrual education in schools, for girls and boys, along with improved training for healthcare professionals to engender better community support and promote quality of life for women as they navigate perimenopausal symptoms and changes. (Post Reproductive Health)

To control spending on semaglutide (Wegovy, Ozempic) for weight loss, Connecticut’s state employee health plan is requiring that members first enter a lifestyle management program. (Politico)

Please enable JavaScript to view the

comments powered by Disqus.